210 related articles for article (PubMed ID: 19765845)
1. Dose-volume effects for normal tissues in external radiotherapy: pelvis.
Fiorino C; Valdagni R; Rancati T; Sanguineti G
Radiother Oncol; 2009 Nov; 93(2):153-67. PubMed ID: 19765845
[TBL] [Abstract][Full Text] [Related]
2. [Dosimetric factors predictive of late toxicity in prostate cancer radiotherapy].
de Crevoisier R; Fiorino C; Dubray B
Cancer Radiother; 2010 Oct; 14(6-7):460-8. PubMed ID: 20797890
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
4. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.
Mell LK; Tiryaki H; Ahn KH; Mundt AJ; Roeske JC; Aydogan B
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1504-10. PubMed ID: 18640499
[TBL] [Abstract][Full Text] [Related]
6. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
[TBL] [Abstract][Full Text] [Related]
7. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective.
Crook J; Esche B; Futter N
Urology; 1996 Mar; 47(3):387-94. PubMed ID: 8633407
[TBL] [Abstract][Full Text] [Related]
8. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
[TBL] [Abstract][Full Text] [Related]
9. Predictive models of toxicity in external radiotherapy: dosimetric issues.
Fiorino C; Rancati T; Valdagni R
Cancer; 2009 Jul; 115(13 Suppl):3135-40. PubMed ID: 19544542
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
[TBL] [Abstract][Full Text] [Related]
11. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
[TBL] [Abstract][Full Text] [Related]
12. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study.
Fiorino C; Fellin G; Rancati T; Vavassori V; Bianchi C; Borca VC; Girelli G; Mapelli M; Menegotti L; Nava S; Valdagni R
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1130-7. PubMed ID: 17881142
[TBL] [Abstract][Full Text] [Related]
13. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101).
Rancati T; Fiorino C; Gagliardi G; Cattaneo GM; Sanguineti G; Borca VC; Cozzarini C; Fellin G; Foppiano F; Girelli G; Menegotti L; Piazzolla A; Vavassori V; Valdagni R
Radiother Oncol; 2004 Oct; 73(1):21-32. PubMed ID: 15465142
[TBL] [Abstract][Full Text] [Related]
14. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
[TBL] [Abstract][Full Text] [Related]
15. Practical aspects of inverse-planned intensity-modulated radiation therapy for prostate cancer: a radiation treatment planner's perspective.
Parker W; Patrocinio H
Can J Urol; 2005 Jun; 12 Suppl 2():48-52. PubMed ID: 16018834
[TBL] [Abstract][Full Text] [Related]
16. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
17. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study.
Fellin G; Fiorino C; Rancati T; Vavassori V; Baccolini M; Bianchi C; Cagna E; Gabriele P; Mauro F; Menegotti L; Monti AF; Stasi M; Valdagni R
Radiother Oncol; 2009 Nov; 93(2):197-202. PubMed ID: 19828205
[TBL] [Abstract][Full Text] [Related]
18. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique.
Ganswindt U; Paulsen F; Corvin S; Hundt I; Alber M; Frey B; Stenzl A; Bares R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):347-55. PubMed ID: 17236960
[TBL] [Abstract][Full Text] [Related]
19. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?
Sanguineti G; Cavey ML; Endres EJ; Franzone P; Barra S; Parker BC; Marcenaro M; Colman M; Agostinelli S; Foppiano F; Vitale V
Strahlenther Onkol; 2006 Sep; 182(9):543-9. PubMed ID: 16944377
[TBL] [Abstract][Full Text] [Related]
20. Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer.
Chan LW; Xia P; Gottschalk AR; Akazawa M; Scala M; Pickett B; Hsu IC; Speight J; Roach M
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):69-77. PubMed ID: 18342454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
